Lung cancer patients treated with radiotherapy bearing C‐G‐T haplotype had about twofold higher risk of RP than those bearing T‐A‐C haplotype, strongly suggesting that the genetic variants of SP‐D could be a genetic biomarker in predicting RP development among lung cancer patients. Here, SFTPD is linked to lung carcinoma.